Use the hyperlinks, where available to access additional clinical trial information.
A multi-arm multi-stage, multi-centre, phase III (MAMS) platform trial that aims to assess hypotheses against a common standard-of-care control arm for the management of people with glioblastoma
Other Non-Commercial Sponsor
National Health & Medical Research Council (NHMRC)
This trial is trying to understand: (1) whether to give metronomic temozolomide as soon as possible following surgery and prior to chemoradiotherapy; and (2) whether to give 6 cycles of standard schedule adjuvant temozolomide chemotherapy (5/28 day cycles) after chemoradiotherapy, or continue temozolomide until progression. Patients will be randomised to a specific arm of treatment, unless they decide not to participate in the randomisation process and are instead assigned to an arm at their clinician's discretion.